Archive for July 12th, 2012

HEB to resubmit Ampligen NDA 3Q 2012. IMGN offering. OREX cardio trial update. TSPT receives aNDA notification + HGSI QLTI updates

Jul 12, 2012 No Comments by

Hemispherx Biopharma, Inc. (NYSE MKT: HEB) said that it plans to resubmit its New Drug Application (NDA) of Ampligen for the treatment of Chronic Fatigue Syndrome (CFS), in 3Q 2012. This is in response to a Complete Response Letter (CRL) issued by the FDA in 2009. The FDA has advised that, once submitted, the complete response […]

Daily News Read more